Across TCGA pan-cancer cohorts, BEST4 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated BEST4 data layer compared with 20 for mass-spec protein.
The strongest signal is observed in ovarian serous cystadenocarcinoma (OV), where higher BEST4 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated BEST4 expression acts as an unfavorable survival marker.
OV and LUAD are the cancer types where BEST4 Mutation most reproducibly stratifies survival.